$174.56+0.28%Close 13 Nov 2026 · Market value $11.03B
About DaVita
DaVita is a healthcare provider focused on kidney care, offering services across the continuum from slowing chronic kidney disease progression to supporting transplantation. Its largest line of business is U.S. dialysis, which provides outpatient hemodialysis, hospital inpatient dialysis, home-based hemodialysis and peritoneal dialysis, along with related laboratory services for patients with end stage kidney disease. Its ancillary services include integrated kidney care management for health plans and government programs, clinical research, a transplant software business and a venture group. The company also operates international dialysis centers in 14 countries outside the U.S. Its U.S. outpatient dialysis centers are located in 46 states and the District of Columbia, and it serves patients largely through government-based programs and commercial insurance plans.
A summary of the business section of the company's latest annual report, filed 11 Feb 2026.
Company facts
| Ticker | DVA · NYSE |
|---|
| Sector | Healthcare |
|---|
| Industry | Health Care Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 927066 |
|---|
| Latest annual report | 10-K, filed 11 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Javier J. Rodriguez | Chief Executive Officer · Director | 845K · 1.3% | Open-market sale, 16 Jun 2026 |
|---|
| Joel Ackerman | CFO and Treasurer | 162K · < 1% | Open-market sale, 7 May 2026 |
|---|
| Kathleen A. Waters | Chief Legal & Pub. Affairs Off | 106K · < 1% | Open-market sale, 15 Jun 2026 |
|---|
| David P. Maughan | Chief Operating Officer, DKC | 47.1K · < 1% | Shares withheld for tax, 22 Sep 2026 |
|---|
| James O. Hearty | Chief Compliance Officer | 31.3K · < 1% | Open-market sale, 15 May 2026 |
|---|
| Pamela M. Arway | Director | 26.7K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Phyllis R. Yale | Director | 14.3K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Barbara J. Desoer | Director | 13.8K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Gregory J. Moore, M.D., Ph.D. | Director | 7.6K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Jason M. Hollar | Director | 6.4K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Adam H. Schechter | Director | 5.4K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Wendy L. Schoppert | Director | 3.6K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| Dennis W. Pullin | Director | 2.4K · < 1% | Grant or award, 15 Aug 2026 |
|---|
| BERRY CHRISTOPHER MICHAEL | Chief Accounting Officer | — | Grant or award, 15 Mar 2026 |
|---|
| BERG CHARLES | Director | — | Grant or award, 15 May 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
DVA in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.